Indication:Mutation-positive metastatic colorectal cancer in adults
Colorectal cancer (metastatic) only (First-line treatment
NICE TA668 recommends encorafenib plus cetuximab, as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment only if the company provides it according to the commercial arrangements.
MHRA Drug Safety Update
Importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer; http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON377644